| Metric | Value ($ M) | Q1 FY25 |
|---|---|---|
| Revenue | 0.99 | 296.0% |
| Total Income | 0.99 | 296.0% |
| Expenditure | 6.33 | 9.7% |
| PBT | — | |
| Net Profit | -6.66 | 22.9% |
| OPM | — | |
| NPM | — | |
| EPS | — |
VolitionRx Limited Announces Q1 2026 Financial Results and Business Update
15 May 2026 · 15 May, 1:53 am
Summary
VolitionRx Limited announced its financial results and business update for the first quarter of 2026. The company's revenue for the quarter was approximately $1.0 million, compared to $0.2 million for the same period in 2025. The operating loss decreased by 3% compared to the same quarter in 2025. The company is actively pursuing licensing agreements and other arrangements to generate revenue through milestone payments and royalties.
Key Highlights
- 1
VolitionRx Limited's revenue for the first quarter was approximately $1.0 million, compared to $0.2 million for the same period in 2025.
- 2
The company's operating loss was down 3% for the quarter versus the comparable quarter in 2025.
- 3
Net cash used in operating activities was $5.3 million during the quarter.
- 4
The company received $5.4 million in net proceeds from equity sales through their at-the-market facility.
- 5
VolitionRx also received $1.9 million in net proceeds from the issuance of a convertible note and warrant.
- 6
The company secured $1 million of non-dilutive funding from agencies of the Walloon Region, with an additional approximate $0.9 million expected over the next 12 months.
Management Comments
Cameron Reynolds
“We have made strong progress across all of our product pillars during the first quarter and indeed subsequent to quarter end. “We announced the submission for peer review of a clinical manuscript reporting the high accuracy of our Nu.Q® Vet feline prototype assay in detecting lymphoma in cats, our third species. The publication of this study in a peer reviewed journal is expected subsequently to unlock a $5 million contractual milestone payment. The feline test could greatly expand the market of our Nu.Q® Vet platform. “We are working with our long-term collaborators at the Hospices Civils de Lyon, one of Europe's leading cancer centers, on the reimbursement submission for Nu.Q® Lung Cancer. Reimbursement is the last step on the path to the first use of Nu.Q® in routine clinical practice, an exciting prospect which is core to Volition's mission, using our tests to help save lives. “We reported two new, potentially large, clinical use cases for our Nu.Q® NETs assay beyond sepsis. In conjunction with the Mayo Clinic1, we demonstrated Nu.Q® NETs’ potential clinical utility in aiding early risk identification which could inform targeted preventive strategies in acute trauma care. We also demonstrated potential use for patient management of a chronic disease, Hidradenitis Suppurativa,2 which affects about 1% of the world’s population. Both use cases have the potential to be large markets. “We are currently in discussions with more than a dozen of the world’s leading diagnostic and liquid biopsy companies where our goal is to enter into licensing agreements and other arrangements that will bring revenue in the form of up front milestone payments, royalties and/or other recurring revenue. “We are delighted to have grown the commercial interest in the first quarter, particularly with regards to our Capture-Seq™ technology, with an increase in discussions, including for technical evaluations. “Discussions are at various stages of the negotiation process across all our different pillars; our laser focus is on executing licensing agreements and we will update you as they progress.”
Informational and educational content only. Not investment advice.